Biosafety Testing for Biologics and Viral Vaccines

Translate Insights into Novel Strategies for Viral Vaccine Research

Vaccines are a potent and cost-effective method of preventing deadly diseases. The recent global outbreak of COVID-19 caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) serves as a stark reminder of the imminent threat of unexpected pathogens.

Researchers around the world are responding quickly to create a vaccine to combat the pandemic. However, creation of a human viral vaccine generally takes 10–20 years, but that is the kind of time we do not have when faced with an ongoing pandemic. Even in absence of a pandemic, many researchers consider 10 years too long for a process of creating such vital, life-saving preventive therapies. We need a deeper understanding of the cellular and molecular mechanisms that drive immune responses against emerging infectious diseases (EIDs).

The goal, then, is to accelerate the viral vaccine development process.

Although a great deal of progress has been made in vaccine research, recent headlines remind us that we still have much to do to advance and accelerate the discovery process.

This eBook features a collection of articles and studies that focus on novel groundbreaking research and developmental strategies that have enabled scientists to unravel the complexity of viral biology with new insights and innovative approaches to expedite the discovery and development of new vaccines against viral infections.

Key topics:

• Influenza Vaccination Protects against Pandemic H1N1 Infection in Sickle Cell Disease Mice
• Microparticle Release from Cell Lines and Its Anti-Influenza Activity
• Serological and T Cell Responses After Varicella Zoster Virus Vaccination in HIV-Positive Patients Undergoing Renal Dialysis
• A Kinase Inhibitor Phenotypic Screen Using a Novel Multiplex T Cell Activation Assay
• Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists